[1] Ferlay J,Soerjomataram I,Dikshit R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-386. [2] Clavien PA,Lesurtel M,Bossuyt PM,et al.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J].Lancet Oncol,2012,13(1):e11-22. [3] Vitale A,Peck-Radosavljevic M,Giannini EG,et al.Personalized treatment of patients with very early hepatocellular carcinoma[J].J Hepatol,2017,66(2):412-423. [4] Greten TF,Lai CW,Li G,et al.Targeted and immune-based therapies for hepatocellular carcinoma[J].Gastroenterology,2019,156(2):510-524. [5] Kulik L,Elserag HB.Epidemiology and management of hepatocellular carcinoma[J].Gastroenterology,2019,156(2):477-491. [6] Kabelitz D,Wesch D,He W.Perspectives of gammadelta T cells in tumor immunology[J].Cancer Res,2007,67(1):5-8. [7] Zhao Y,Niu C,Cui J.Gamma-delta (γδ) T cells: friend or foe in cancer development[J].J Transl Med,2018,16(1):3. [8] Yue C,Yang K,Dong W,et al.γδ T cells in peripheral blood of glioma patients[J].Med Sci Monit,2018,24:1784-1792. [9] Harly C,Peyrat MA,Netzer S,et al.Up-regulation of cytolytic functions of human Vδ2-γ T lymphocytes through engagement of ILT2 expressed by tumor target cells[J].Blood,2011,117(10):2864-2873. [10] Kabelitz D,Kalyan S,Oberg HH,et al.Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity[J].Oncoimmunology,2013,2(3):e23304. [11] Zhao H,Xi X,Cui L,et al.CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity[J].Cell Mol Immunol,2012,9(2):147-154. [12] Meraviglia S,Eberl M,Vermijlen D,et al.In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients[J].Clin Exp Immunol,2010,161(2):290-297. [13] Kress E,Hedges JF,Jutila MA,et al.Distinct gene expression in human Vdelta1 and Vdelta2 gammadelta T cells following non-TCR agonist stimulation[J].Mol Immunol,2006,43(12):2002-2011. [14] Zhou J,Kang N,Cui L,et al.Anti-γδ TCR antibody-expanded γδ T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies[J].Cell Mol Immunol,2012,9(1):34-44. [15] Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380 (15):1450-1462. [16] Yuen MF,Chen DS,Dusheiko GM,et al.Hepatitis B virus infection[J]. Nat Rev Dis Primers,2018,4:18035. [17] Kimura Y,Nagai N,Tsunekawa N,et al.IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression[J].Cancer Sci,2016,107(9):1206-1214. [18] Reboursiere E,Gac AC,Garnier A,et al.Increased frequencies of circulating and tumor-resident Vδ1+ T cells in patients with diffuse large B-cell lymphoma[J].Leuk Lymphoma,2018,59(1):187-195. [19] Simöes C,Silva I,Carvalho A,et al. Quantification and phenotypic characterization of peripheral blood Vδ1+T cells in chronic lymphocytic leukemia and monoclonal B cell lymphocytosis[J].Clin Cytom,2019,96(2):164-168. [20] Chen X,Shang W,Xu R,et al.Distribution and functions of γδ T cells infiltrated in the ovarian cancer microenvironment[J].J Transl Med,2019,17(1):144. [21] Peng G,Wang HY,Peng W,et al.Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway[J].Immunity,2007,27(2):334-348.
2020, Vol. 27 
